Predictors of the risk of fibrosis at 10 years after breast conserving therapy for early breast cancer -- A study based on the EORTC trial 22881-10882 'boost versus no boost'.

MLA

Collette S, et al. “Predictors of the Risk of Fibrosis at 10 Years after Breast Conserving Therapy for Early Breast Cancer -- A Study Based on the EORTC Trial 22881-10882 ‘Boost versus No Boost.’” European Journal of Cancer, vol. 44, no. 17, Nov. 2008, pp. 2587–99. EBSCOhost, https://doi.org/10.1016/j.ejca.2008.07.032.

APA

Collette S, Collette L, Budiharto T, Horiot J, Poortmans PM, Struikmans H, Van den Bogaert W, Fourquet A, Jager JJ, Hoogenraad W, Mueller R, Kurtz J, Morgan DAL, Dubois J, Salamon E, Mirimanoff R, Bolla M, Van der Hulst M, Wárlám-Rodenhuis CC, & Bartelink H. (2008). Predictors of the risk of fibrosis at 10 years after breast conserving therapy for early breast cancer -- A study based on the EORTC trial 22881-10882 “boost versus no boost.” European Journal of Cancer, 44(17), 2587–2599. https://doi.org/10.1016/j.ejca.2008.07.032

Chicago

Collette S, Collette L, Budiharto T, Horiot J, Poortmans PM, Struikmans H, Van den Bogaert W, et al. 2008. “Predictors of the Risk of Fibrosis at 10 Years after Breast Conserving Therapy for Early Breast Cancer -- A Study Based on the EORTC Trial 22881-10882 ‘Boost versus No Boost.’” European Journal of Cancer 44 (17): 2587–99. doi:10.1016/j.ejca.2008.07.032.